Peptide Receptor Radionuclide Therapy or Everolimus in Metastatic Neuroendocrine Tumors: The SeqEveRIV Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network.

RPEP-082082024Fosse, Aurelien; Hadoux, Julien; Girot, Paul; Beron, Amandine; Afchain, Pauline; Cottereau, Anne-Segolene; Baudin, Eric; Dierickx, Lawrence O; Lecomte, Thierry; Perrier, Marine; Lepage, Come; Bouhier-Leporrier, Karine; Goichot, Bernard; Lachachi, Boumediene; Walter, Thomas; Durand, Alice

evidence

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

Read the original research

Peptide Receptor Radionuclide Therapy or Everolimus in Metastatic Neuroendocrine Tumors: The SeqEveRIV Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 65(9), 1416-1422

View on PubMed ↗Publisher’s paper ↗

Citation

Fosse, Aurelien; Hadoux, Julien; Girot, Paul; Beron, Amandine; Afchain, Pauline; Cottereau, Anne-Segolene; Baudin, Eric; Dierickx, Lawrence O; Lecomte, Thierry; Perrier, Marine; Lepage, Come; Bouhier-Leporrier, Karine; Goichot, Bernard; Lachachi, Boumediene; Walter, Thomas; Durand, Alice. (2024). Peptide Receptor Radionuclide Therapy or Everolimus in Metastatic Neuroendocrine Tumors: The SeqEveRIV Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 65(9), 1416-1422. https://doi.org/10.2967/jnumed.123.267363